- Total Revenue in Q3 was $22.3
Million
- SaaS revenue of $15.9 million in Q3,
up 5% from $15.2 million in prior year Q3
- Enhanced efficiencies continued to
drive reduced operating expenses and improved adjusted bottom line
results
- Sequencing and Molecular Analysis,
930 total tests ordered in Q3, including 461 GPS Cancer® and 469
Liquid GPS® Tests; continued sequential quarterly growth in total
tests ordered
- Appointed new executives to lead the
company’s strategy and business development, as well as global
sales
- SaaS business hit all time high with
approximately 80 million covered lives across Eviti and
NaviNet
NantHealth, Inc. (NASDAQ-GS: NH), a next-generation,
evidence-based, personalized healthcare company, today reported
financial results for its third quarter ended September 30,
2018.
Sequencing and Molecular Analysis – Highlights
- In September 2018, at the IASLC
19th World Conference on Lung Cancer, the company
and NantOmics presented two posters and a mini-oral presentation
titled “Blood Based Biomarkers: RNA, KRAS and PD-L1 Strongly
Matching with Tissue and Showing Correlation with Clinical
Responses In NSCLC Patients,” with investigational data showing (i)
association between clinical response and changes in plasma cfRNA
levels and (ii) that plasma levels of PD-L1 expression, while on
immunotherapy, could be used to monitor clinical responses.
- In October 2018, at ESMO, the
world’s second largest cancer symposium, the company, along with
NantOmics, conducted one oral presentation and presented four
papers, including papers demonstrating the promise of Liquid GPS,
the company’s blood-based molecular test that provides oncologists
with a powerful tool for non-invasive tumor profiling and
quantitative monitoring of treatment response.
- Expanded Sequencing and Molecular
Analysis Reimbursement Arrangements: In Q3, the company
expanded its GPS reimbursement contract with a large, national
employer in the healthcare industry to include reimbursement for
its Liquid GPS test and, in Q4, the company expanded GPS Cancer and
Liquid GPS coverage for firefighters through the execution of an
additional reimbursement contract benefiting members of a city-wide
firefighter union.
“We recently made two oral presentations at major medical
congresses, highlighting the unique aspects of our liquid biopsy
platform that are different from ctDNA platforms offered by
Guardant Health, Foundation Medicine and other laboratories,” said
Sandeep (Bobby) Reddy, M.D., Chief Medical Officer of NantHealth.
“Only Liquid GPS can produce this type of data on chemotherapy
selection and immunotherapy selection. Moreover, the review
committees of two different organizations felt that this data was
sufficiently important to warrant oral presentation. This further
validates our belief that circulating RNA expression, not DNA
alone, is the liquid biopsy technology that will transform medical
practice.”
Software and Services Highlights:
- Payer Engagement (NaviNet):
- In Q3, executed a large-scale
implementation of NaviNet Open Authorizations with a key customer,
adding more than 40,000 end users, bringing total active number of
users to 862,000
- Clinical Decision Support
(Eviti):
- Released new functionality with drug
specific justifications, enabling the capture of key data to ensure
quicker pre-authorization and clinical integrity.
- Completed a new statewide
implementation with a large existing payer in Kentucky, adding
250,000 covered lives. This implementation followed a similar
success in Florida in Q2 for the same national payer.
- Connected Care:
- In Q4, collaborated with B. Braun
Australia, GE Healthcare and iProcedures to demonstrate the
exchange of data between patient devices and medical records at the
HIMSS Interoperability Showcase™ as part of the Healthcare
Information and Management Systems Society (HIMSS) Asia Pacific
Conference.
“We are pleased to report that total net revenue for the 2018
third quarter increased to $22.3 million, up from the comparable
prior year period, as well as on a sequential quarterly basis,”
said Bob Petrou, Interim Chief Financial Officer of NantHealth.
“Looking ahead, the recent addition of two new executives to lead
our strategy and business development, and global sales efforts
will help us expand our business in both the U.S. and international
markets.”
Business and Financial Highlights
The company adopted a new revenue recognition standard on
January 1, 2018. Please note that the financial results presented
below include both amounts “as presented,” which reflect
implementation of the new revenue recognition standard, as well as
amounts prior to the impact of the new revenue recognition standard
to allow for comparability against historical results. Starting in
fiscal year 2019, the company will no longer present its GAAP and
Non-GAAP financial results under the previous revenue recognition
standard. For additional information and reconciliations of our
financial results between the new and previous revenue recognition
standard, see the additional tables included in this press release
and in the company’s Form 10-Q to be filed with the Securities and
Exchange Commission.
For the 2018 third quarter, total net revenue as presented was
$22.3 million. Total 2018 third quarter net revenue prior to the
impact of the new revenue recognition standard increased to $22.0
million from $21.8 million in 2017 third quarter. Gross profit as
presented was $11.1 million, or 50% of total net revenue. Gross
profit prior to the impact of the new revenue recognition standard
was $10.8 million, or 49% of total net revenue, compared with $10.3
million, or 47% of total net revenue, for the prior-year third
quarter. Selling, general and administrative (SG&A) expenses as
presented were $17.0 million. SG&A prior to the impact of the
new revenue recognition standard was $16.9 million compared with
$17.5 million in 2017 third quarter. Research and development
(R&D) expenses as presented decreased to $4.8 million from $7.7
million; the new revenue recognition standard did not impact
R&D expenses.
Financial results for the third quarter of 2018 included a
non-cash charge for loss from related party equity method
investment, including impairment, of $83.3 million. Net loss from
continuing operations, net of tax, as presented was $97.4 million,
or $0.89 per share. Net loss from continuing operations, net of
tax, prior to the impact of the new revenue recognition standard
was $97.5 million, or $0.89 per share, from $23.0 million, or $0.20
per share for the 2017 third quarter. Loss from discontinued
operations, net of tax, as presented was $32,000, or $0.00 per
share, compared with $19.4 million, or $0.17 per share; the new
revenue recognition standard did not impact loss from discontinued
operations. Net loss as presented was $97.5 million, or $0.89 per
share. Net loss prior to the impact of the new revenue recognition
standard was $97.5 million, or $0.89 per share, compared with $42.4
million, or $0.37 per share, for 2017 third quarter.
For the 2018 third quarter, on a non-GAAP basis, adjusted net
loss from continuing operations as presented was $10.8 million, or
$0.10 per share. On a non-GAAP basis, adjusted net loss from
continuing operations prior to the impact of the new revenue
recognition standard was $10.9 million, or $0.10 per share,
compared with $14.9 million, or $0.13 per share, for the 2017 third
quarter.
In August 2017, NantHealth sold its provider/patient engagement
assets to Allscripts to focus on core competencies and accelerate
the plan to achieve profitability. As a result, the company has
classified the current and prior period operating results of its
provider/patient engagement business as discontinued operations.
All results presented above represent the company’s continuing
operations.
Conference Call Information and Forward-Looking
Statements
Later today, the company will host a conference call at 1:30
p.m. PT (4:30 p.m. ET) to review its results of operations for the
third quarter ended September 30, 2018. The conference call will be
available to interested parties by dialing 844-309-3709 from the
U.S. or Canada, or 281-962-4864 from international locations,
passcode 9992769. The call will be broadcast via the Internet at
www.nanthealth.com. Listeners are encouraged to visit the website
at least 10 minutes prior to the start of the scheduled
presentation to register, download and install any necessary audio
software. A playback of the call will be archived and accessible on
the same website for at least three months.
Discussion during the conference call may include
forward-looking statements regarding topics such as the company’s
financial status and performance, regulatory and operational
developments, and other comments the company may make about its
future plans or prospects in response to questions from
participants on the conference call.
Use of Non-GAAP Financial Measures
This news release contains references to Non-GAAP financial
measures, including adjusted net loss and adjusted net loss per
share, which are financial measures that are not prepared in
conformity with United States generally accepted accounting
principles (U.S. GAAP). The Company’s management believes that the
presentation of Non-GAAP financial measures provides useful
supplementary information regarding operational performance,
because it enhances an investor’s overall understanding of the
financial results for the Company’s core business. Additionally, it
provides a basis for the comparison of the financial results for
the Company’s core business between current, past and future
periods. Other companies may define these measures in different
ways. Non-GAAP financial measures should be considered only as a
supplement to, and not as a substitute for or as a superior measure
to, financial measures prepared in accordance with U.S. GAAP.
Non-GAAP per share numbers are calculated based on one class of
common stock and do not incorporate the effects, if any, of using
the two-class method.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, is a next-generation, evidence-based, personalized
healthcare company enabling improved patient outcomes and more
effective treatment decisions for critical illnesses. NantHealth's
unique systems-based approach to personalized healthcare applies
novel diagnostics tailored to the specific molecular profiles of
patient tissue and integrates this molecular data in a clinical
setting with large-scale, real-time biometric signal and phenotypic
data to track patient outcomes and deliver precision medicine. For
nearly a decade, NantHealth has developed an adaptive learning
system that integrates our unique molecular profiling solution,
software and hardware. Our system infrastructure collects, indexes,
analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and
traditional sources to continuously improve decision-making and
optimize our clinical pathways and decision algorithms over time.
For more information please
visit https://www.nanthealth.com/.
About GPS Cancer®
GPS Cancer® is a unique, comprehensive test available through
NantHealth. GPS Cancer integrates tumor/normal DNA and RNA
sequencing, with enhanced expression analysis and bioinformatics of
complex biologic pathway systems, providing oncologists with a
comprehensive molecular profile of a patient’s cancer to inform
personalized treatment strategies. GPS Cancer testing is conducted
in CLIA-certified and CAP-accredited laboratories. For more
information, visit https://www.nanthealth.com/gps-cancer/.
About Liquid GPS®
Liquid GPS is a blood-based molecular test that provides
oncologists with a powerful tool for noninvasive tumor profiling
and quantitative monitoring of treatment response. Liquid GPS looks
beyond cfDNA to cfRNA, which allows profiling and trending of
actionable biomarkers that cannot be assessed through cfDNA alone.
In addition to providing molecular insight into key
guidelines-based biomarkers (e.g., EGFR, ALK, ROS1, KRAS), this
powerful RNA-based approach enables a variety of capabilities and
applications not typically available from a liquid biopsy test. For
more information,
visit https://www.nanthealth.com/liquid-gps/.
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Forward-looking statements can be identified by the
words “expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Risks and uncertainties include, but are not limited to: our
ability to successfully integrate a complex learning system to
address a wide range of healthcare issues; our ability to
successfully amass the requisite data to achieve maximum network
effects; appropriately allocating financial and human resources
across a broad array of product and service offerings; raising
additional capital as necessary to fund our operations; achieving
significant commercial market acceptance for our sequencing and
molecular analysis solutions; establish relationships with, key
thought leaders or payers’ key decision makers in order to
establish GPS Cancer as a standard of care for patients with
cancer; our ability to grow the market for our Systems
Infrastructure, and applications; successfully enhancing our
Systems Infrastructure and applications to achieve market
acceptance and keep pace with technological developments; customer
concentration; competition; security breaches; bandwidth
limitations; our ability to continue our relationship with
NantOmics; our ability to obtain regulatory approvals; dependence
upon senior management; the need to comply with and meet applicable
laws and regulations; unexpected adverse events; clinical adoption
and market acceptance of GPS Cancer; and anticipated cost savings.
We undertake no obligation to update any forward-looking statement
in light of new information or future events, except as otherwise
required by law. Forward-looking statements involve inherent risks
and uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, many of which are
discussed in more detail in our reports filed with the Securities
and Exchange Commission.
NantHealth, Inc. Condensed Consolidated Balance
Sheets (Dollars in thousands, except per share amounts)
September 30,
2018
December 31,
2017
(Unaudited) Assets Current assets Cash and cash
equivalents $ 22,841 $ 61,660 Accounts receivable, net 17,202
11,491 Inventories 654 839 Deferred implementation costs 11 1,960
Related party receivables, net 1,293 585 Prepaid expenses and other
current assets 5,188 5,358 Total
current assets 47,189 81,893 Property, plant, and equipment, net
24,942 18,517 Deferred implementation costs, net of current 3 3,951
Goodwill 115,930 114,625 Intangible assets, net 66,990 69,424
Investment in related party 59,000 156,863 Related party
receivable, net of current 1,611 1,727 Other assets 1,848
2,195 Total assets $ 317,513 $ 449,195
Liabilities and Stockholders' Equity Current
liabilities Accounts payable $ 2,222 $ 3,164 Accrued and other
current liabilities 15,562 18,134 Deferred revenue 14,866 10,057
Related party payables, net 5,283 4,504
Total current liabilities 37,933 35,859 Deferred revenue, net of
current 8,061 7,126 Related party liabilities 16,138 11,500 Related
party promissory note 112,666 112,666 Related party convertible
note, net 8,265 7,947 Convertible notes, net 78,230 74,845 Other
liabilities 5,025 5,950 Total
liabilities 266,318 255,893
Stockholders' equity Common stock, $0.0001 par value per share,
750,000,000 shares authorized; 109,491,277 and 108,383,602 shares
issued and outstanding at September 30, 2018 and December 31, 2017,
respectively (including 3,490 shares of restricted stock at both
dates) 11 10 Additional paid-in capital 886,363 886,669 Accumulated
deficit (834,999 ) (693,233 ) Accumulated other comprehensive loss
(180 ) (144 ) Total stockholders' equity
51,195 193,302 Total liabilities and
stockholders' equity $ 317,513 $ 449,195
NantHealth, Inc. Condensed Consolidated Statements
of Operations (Dollars in thousands, except per share amounts)
(Unaudited) Three Months Ended
September 30,
Nine Months Ended
September 30,
2018 2017
2018 2017 Total net
revenue $ 22,292 $ 21,760 $ 66,603 $ 64,378 Total cost of revenue
11,226 11,472 32,878
32,643
Gross Profit 11,066
10,288 33,725 31,735
Operating Expenses: Selling, general and
administrative 17,001 17,521 56,123 54,181 Research and development
4,835 7,749 15,875 25,051 Amortization of acquisition-related
assets 1,054 1,054 3,163
3,163 Total operating expenses 22,890
26,324 75,161 82,395
Loss from operations (11,824 ) (16,036 ) (41,436 ) (50,660 )
Interest expense, net (4,306 ) (4,067 ) (12,766 ) (12,049 ) Other
income (expense), net 226 60 (928 ) 308 Loss from related party
equity method investment, including impairment (83,306 )
(2,942 ) (89,512 ) (46,353 ) Loss from
continuing operations before income taxes (99,210 ) (22,985 )
(144,642 ) (108,754 ) (Benefit from) provision for income taxes
(1,778 ) 30 (3,429 ) 85
Net loss from continuing operations (97,432 ) (23,015 ) (141,213 )
(108,839 ) Loss from discontinued operations, net of tax (32
) (19,383 ) (1,817 ) (44,738 ) Net loss $
(97,464 ) $ (42,398 ) $ (143,030 ) $ (153,577 )
Net loss
per share: Continuing operations Basic and diluted - common
stock $ (0.89 ) $ (0.20 ) $ (1.29 ) $ (0.91 ) Discontinued
operations Basic and diluted - common stock $ — $ (0.17 ) $
(0.02 ) $ (0.37 ) Total net income (loss) per share Basic
and diluted - common stock $ (0.89 ) $ (0.37 ) $ (1.31 ) $ (1.28 )
Weighted average shares outstanding: Basic and
diluted - common stock 109,471,712 115,924,122
109,060,408 119,745,231
NantHealth, Inc. Condensed Consolidated Statements
of Operations Reconciliation of results under ASC 606 and
ASC 605 (Dollars in thousands, except per share amounts)
(Unaudited)
Three Months Ended
September 30
Nine Months Ended
September 30
As Reported Adjustments due to ASC 606
Without new Revenue Standard As Reported
Adjustments due to ASC 606 Without new Revenue
Standard 2018 2018
2018 2018
Total net revenue 22,292 (258 ) 22,034 66,603 (1,615 )
64,988 Total cost of revenue 11,226 (29 )
11,197 32,878 (111 )
32,767
Gross Profit 11,066 (229
) 10,837 33,725 (1,504 )
32,221
Operating Expenses: Selling, general
and administrative 17,001 (59 ) 16,942 56,123 425 56,548 Research
and development 4,835 — 4,835 15,875 — 15,875 Amortization of
acquisition-related assets 1,054 —
1,054 3,163 —
3,163 Total operating expenses 22,890
(59 ) 22,831 75,161 425
75,586 Loss from operations (11,824 ) (170 )
(11,994 ) (41,436 ) (1,929 ) (43,365 ) Interest expense, net (4,306
) — (4,306 ) (12,766 ) — (12,766 ) Other income (expense), net 226
— 226 (928 ) — (928 ) Loss from related party equity method
investment, including impairment (83,306 ) —
(83,306 ) (89,512 ) — (89,512 )
Loss from continuing operations before income taxes (99,210 ) (170
) (99,380 ) (144,642 ) (1,929 ) (146,571 ) Benefit from income
taxes (1,778 ) (110 ) (1,888 ) (3,429 )
(349 ) (3,778 ) Net loss from continuing operations
(97,432 ) (60 ) (97,492 ) (141,213 ) (1,580 ) (142,793 ) Loss from
discontinued operations, net of tax (32 ) —
(32 ) (1,817 ) — (1,817 ) Net
loss $ (97,464 ) (60 ) (97,524 ) $ (143,030 ) $
(1,580 ) (144,610 )
Net loss per share: Basic
and diluted - common stock $ (0.89 ) $ — $ (0.89 ) $ (1.31 )
$ (0.02 ) $ (1.33 )
Weighted average shares
outstanding: Basic and diluted - common stock
109,471,712 — 109,471,712
109,060,408 — 109,060,408
NantHealth, Inc. Supplemental
Revenue Schedule (Dollars in thousands)
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2018 2017 2018
2017 Revenue: Software-as-a-service related $
15,937 $ 15,205 $ 48,323 $ 44,948 Software and hardware related
1,450 1,523 3,790 5,400 Maintenance 2,522 2,696
7,357 8,183 Total software-related revenue 19,909
19,424 59,470 58,531 Sequencing and molecular analysis 742 1,025
2,506 1,985 Home health care services 1,641 1,311
4,627 3,862 Total net revenue $ 22,292 $ 21,760 $
66,603 $ 64,378
Cost of Revenue:
Software-as-a-service related $ 5,863 $ 5,859 $ 18,205 $ 17,287
Software and hardware related 737 1,757 2,412 3,785 Maintenance 234
274 683 564 Amortization of developed technologies 1,233
1,143 3,700 4,029 Total software-related cost
of revenue 8,067 9,033 25,000 25,665 Sequencing and molecular
analysis 2,323 1,757 5,443 4,862 Home health care services
836 682 2,435 2,116 Total cost of revenue $
11,226 $ 11,472 $ 32,878 $ 32,643
NantHealth,
Inc. Non-GAAP Net Loss from Continuing Operations and
Non-GAAP Net Loss Per Share from
Continuing Operations
(Dollars in thousands, except per share amounts)
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2018 2017
2018 2017 Net loss from
continuing operations $ (97,432 ) $ (23,015 ) $ (141,213 ) $
(108,839 ) Adjustments to GAAP net loss: Loss from related party
equity method investment including impairment loss 83,306 2,942
89,512 46,353 Stock-based compensation expense from continuing
operations 373 (170 ) 4,805 (485 ) Corporate restructuring from
continuing operations — 807 — 2,396 Acquisition related sales
incentive 425 727 995 2,061 Change in fair value of derivatives
liability (5 ) (6 ) (7 ) (245 ) Noncash interest expense related to
convertible notes 1,273 1,121 3,702 3,260 Intangible amortization
from continuing operations 2,287 2,197 6,863 7,192 Securities
litigation costs 887 500 1,709 685 Impairment of equity securities
— — 1,750 — Tax benefit resulting from certain noncash tax items
(1,943 ) — (3,649 ) —
Total adjustments to GAAP net loss from continuing operations
86,603 8,118 105,680
61,217 Net loss - Non-GAAP from continuing operations
$ (10,829 ) $ (14,897 ) $ (35,533 ) $ (47,622 ) Weighted
average shares outstanding 109,471,712
115,924,122 109,060,408 119,745,231
Net loss per share from continuing operations -
Non-GAAP $ (0.10 ) $ (0.13
) $ (0.33 ) $ (0.40
) Reconciliation of Net Loss from Continuing
Operations per Common Share
to Net Loss per Common Share from
Continuing Operations - Non-GAAP (Unaudited):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2018 2017
2018 2017 Net loss per common
share from continuing operations $ (0.89 ) $ (0.20 ) $ (1.29 ) $
(0.91 ) Adjustments to GAAP net loss per common share from
continuing operations: Loss from related party equity method
investment including impairment loss 0.77 0.03 0.82 0.39
Stock-based compensation expense from continuing operations — —
0.04 — Corporate restructuring from continuing operations — 0.01 —
0.02 Acquisition related sales incentive — 0.01 0.01 0.02 Change in
fair value of derivatives liability — — — — Noncash interest
expense related to convertible notes 0.01 0.01 0.03 0.03 Intangible
amortization from continuing operations 0.02 0.01 0.05 0.04
Securities litigation costs 0.01 — 0.02 0.01 Impairment of equity
securities — — 0.02 — Tax benefit resulting from certain noncash
tax items (0.02 ) — (0.03 ) —
Total adjustments to GAAP net loss per common share from
continuing operations 0.79 0.07
0.96 0.51
Net loss per common share from
continuing operations - Non-GAAP $ (0.10 )
$ (0.13 ) $ (0.33 )
$ (0.40 )
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181115005873/en/
Investor Contact:Robert Jafferjaffe@rjaffeco.com424.288.4098
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2023 to Apr 2024